Francesca Gay - Concepedia

Author

Francesca Gay

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino ORCID

Also Known As

F Gay, F. Gay, Francesa Gay, Francesca Gay, Francesca M. Gay

439

Publications

17.6K

Citations

H-Index

Concepts

All Affiliations

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino University of Turin Istituti di Ricovero e Cura a Carattere Scientifico Erasmus MC Cancer Institute Azienda Ospedaliero Universitaria San Giovanni Battista

About

Francesca Gay is an author at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino specializing in oncology, medicine, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	45	3.9K
2	Health Sciences	23	27	2.4K
3	Blood Transplantation	4	4	548
4	Cell Biology	2	2	86
5	Public Health	1	1	15

Francesca Gay

122

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group Antonio Palumbo, Hervé Avet‐Loiseau, Stefania Oliva, Journal of Clinical Oncology	2015	2.1K
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma Antonio Palumbo, Federica Cavallo, Francesca Gay, New England Journal of Medicine	2014	774
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro, New England Journal of Medicine	2023	435
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications Evangelos Terpos, Martina Kleber, Monika Engelhardt, Haematologica Bone DiseaseHematological MalignancyZoledronic AcidEuropean Myeloma NetworkMedicine	2015	391
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Michèle Cavo, Francesca Gay, Meral Beksaç, The Lancet Haematology Hematological MalignancyTransplantationMarrow TransplantationMedicineStem Cell Transplantation	2020	377
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project Mattia D’Agostino, David A. Cairns, Juan José Lahuerta, Journal of Clinical Oncology	2022	371
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Antonio Palumbo, Sara Bringhen, Anna Marina Liberati, Blood	2008	357
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer Harry Bleiberg, Thierry Conroy, B Paillot, European Journal of Cancer Esophageal CancerGastrointestinal OncologyMedicinePathologyPhase Ii Study	1997	347
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network Antonio Palumbo, Patrizia Falco, Paolo Corradini, Journal of Clinical Oncology	2007	316
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, The Lancet Oncology Hematological MalignancyTransplantationMarrow TransplantationMedicineImmunology	2015	312

Page 1